Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History AKBA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics AKBA

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Akebia Ther

AKBA
Current price
3.62 USD -0.01 USD (-0.28%)
Last closed 3.63 USD
ISIN US00972D1054
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 950 742 272 USD
Yield for 12 month +281.86 %
1Y
3Y
5Y
10Y
15Y
AKBA
21.11.2021 - 28.11.2021

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Address: 245 First Street, Cambridge, MA, United States, 02142

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

7.40 USD

P/E Ratio

Dividend Yield

Financials AKBA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures AKBA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+160 180 000 USD

Last Year

+194 623 000 USD

Current Quarter

+57 336 000 USD

Last Quarter

+46 497 000 USD

Current Year

+97 003 000 USD

Last Year

+120 474 000 USD

Current Quarter

+49 711 000 USD

Last Quarter

+26 132 000 USD
EBITDA 10 202 000 USD
Operating Margin TTM 23.85 %
Price to Earnings
Return On Assets TTM -4.26 %
PEG Ratio
Return On Equity TTM -553.45 %
Wall Street Target Price 7.40 USD
Revenue TTM 184 908 992 USD
Book Value 0.094 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 75.80 %
Dividend Yield
Gross Profit TTM 153 314 000 USD
Earnings per share -0.21 USD
Diluted Eps TTM -0.21 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -24.51 %

Stock Valuation AKBA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 4.82
Price Sales TTM 5.14
Enterprise Value EBITDA 135.34
Price Book MRQ 38.68

Technical Indicators AKBA

For 52 Weeks

0.92 USD 4.08 USD
50 Day MA 3.07 USD
Shares Short Prior Month 20 053 575
200 Day MA 2.15 USD
Short Ratio 3.02
Shares Short 18 498 837
Short Percent 7.12 %